Stock 002019 YIFAN PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Yifan Pharmaceutical Co., Ltd. Stock

Equities

002019

CNE000001K65

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-04-23 pm EDT 		5-day change 1st Jan Change
12.66 CNY +5.32% Intraday chart for Yifan Pharmaceutical Co., Ltd. +13.75% -14.34%
Apr. 23 Yifan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 19 Yifan Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Financials

Sales 2024 * 5.22B 720M Sales 2025 * 6.5B 897M Capitalization 15.43B 2.13B
Net income 2024 * 560M 77.28M Net income 2025 * 742M 102M EV / Sales 2024 * 2.96 x
Net cash position 2024 * - 0 Net cash position 2025 * - 0 EV / Sales 2025 * 2.37 x
P/E ratio 2024 *
27.5 x
P/E ratio 2025 *
20.9 x
Employees 4,338
Yield 2024 *
-
Yield 2025 *
-
Free-Float 52.82%
More Fundamentals * Assessed data

Chart Yifan Pharmaceutical Co., Ltd.

Dynamic Chart

Latest news about Yifan Pharmaceutical Co., Ltd.

Yifan Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Yifan Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Yifan Pharmaceutical Gets EU Nod to Sell Ryzneuta Drug MT
Tranche Update on Yifan Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on August 31, 2023. CI
Yifan Pharmaceutical Co., Ltd.'s Equity Buyback announced on August 31, 2023, has closed with 2,412,900 shares, representing 0.2% for CNY 38 million. CI
Yifan Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Tranche Update on Yifan Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on August 31, 2023. CI
Yifan Pharmaceutical Co., Ltd. announces an Equity Buyback for CNY 50 million worth of its shares. CI
Yifan Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Yifan Pharmaceutical Co., Ltd. authorizes a Buyback Plan. CI
Yifan Pharma CFO Resigns; Successor Named MT
Yifan Pharma Registers Leukemia Drug in China MT
Yifan Pharmaceutical Registers Coronary Syndrome Treatment MT
Yifan Pharmaceutical Unit Registers Cancer Treatment in China MT
Yifan Pharmaceutical Registers Dopamine Hydrochloride MT
More news

News in other languages on Yifan Pharmaceutical Co., Ltd.

En Chine, 182 nouveaux milliardaires en un an
More news

Quotes and Performance

1 day+5.32%
1 week+13.75%
Current month+14.26%
1 month+10.96%
3 months+2.34%
6 months+0.88%
Current year-14.34%
More quotes

Highs and lows

1 week
10.85
Extreme 10.85
12.83
1 month
10.74
Extreme 10.74
12.83
Current year
9.11
Extreme 9.11
15.30
1 year
9.11
Extreme 9.11
16.86
3 years
9.11
Extreme 9.11
21.26
5 years
9.11
Extreme 9.11
34.36
10 years
7.66
Extreme 7.664
34.36
More quotes

Managers and Directors - Yifan Pharmaceutical Co., Ltd.

Managers TitleAgeSince
Xian Feng Cheng CHM
 Chairman 56 14-10-14
Guo Han Xu CHM
 Chairman 57 14-09-30
De Qi Feng BRD
 Director/Board Member 45 16-04-27
Members of the board TitleAgeSince
Hongquan Liu BRD
 Director/Board Member 65 20-11-26
Xian Feng Cheng CHM
 Chairman 56 14-10-14
Ben Yu Zhou BRD
 Director/Board Member 51 14-10-14
More insiders

Quotes

Date Price Change Volume
24-04-24 12.66 +5.32% 32,231,680
24-04-23 12.02 +5.81% 18,538,010
24-04-22 11.36 +3.93% 14,487,100
24-04-19 10.93 -0.82% 6,892,650
24-04-18 11.02 -0.99% 6,720,009

End-of-day quote Shenzhen S.E., April 23, 2024

More quotes

Company Profile

YIFAN XINFU PHARMACEUTICAL CO.,LTD, is a China-based company primarily engaged in production and sale of polymer materials. The Company operates in three segments, including Pharmaceuticals, Pharmaceutical Raw Material and Intermediates, as well as Polymer Materials. The Company's main products include D-calcium pantothenate, D- panthenol, poly butylenes succinate and others. The Company distributes its products in domestic and overseas markets.
Sector
Pharmaceuticals
Calendar
2024-04-29 - Q1 2024 Earnings Release
More about the company

Income Statement Evolution

More financial data

Ratings for Yifan Pharmaceutical Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
12.66 CNY
Average target price
18.33 CNY
Spread / Average Target
+44.79%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Generic Pharmaceuticals

1st Jan change Capi.
YIFAN PHARMACEUTICAL CO., LTD. Stock Yifan Pharmaceutical Co., Ltd.
-14.34% 2.13B
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+19.57% 42.78B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+18.59% 22.25B
SANDOZ GROUP AG Stock Sandoz Group AG
+13.05% 14.39B
CIPLA LIMITED Stock Cipla Limited
+12.09% 13.55B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+35.43% 11.27B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-9.80% 6.95B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+6.29% 5.01B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 002019 Stock